ONVO vs. MBOT, AIM, ACHL, NKGN, CYTH, SRZN, QNCX, INKT, ESLA, and PLUR
Should you be buying Organovo stock or one of its competitors? The main competitors of Organovo include Microbot Medical (MBOT), AIM ImmunoTech (AIM), Achilles Therapeutics (ACHL), NKGen Biotech (NKGN), Cyclo Therapeutics (CYTH), Surrozen (SRZN), Quince Therapeutics (QNCX), MiNK Therapeutics (INKT), Estrella Immunopharma (ESLA), and Pluri (PLUR). These companies are all part of the "medical" sector.
Organovo (NASDAQ:ONVO) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends.
Organovo has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.
Microbot Medical received 151 more outperform votes than Organovo when rated by MarketBeat users. Likewise, 70.67% of users gave Microbot Medical an outperform vote while only 50.00% of users gave Organovo an outperform vote.
In the previous week, Microbot Medical had 3 more articles in the media than Organovo. MarketBeat recorded 13 mentions for Microbot Medical and 10 mentions for Organovo. Organovo's average media sentiment score of 0.87 beat Microbot Medical's score of 0.08 indicating that Organovo is being referred to more favorably in the media.
Microbot Medical has a consensus price target of $7.00, indicating a potential upside of 548.15%. Given Microbot Medical's higher probable upside, analysts clearly believe Microbot Medical is more favorable than Organovo.
8.2% of Organovo shares are held by institutional investors. Comparatively, 16.3% of Microbot Medical shares are held by institutional investors. 4.0% of Organovo shares are held by insiders. Comparatively, 10.6% of Microbot Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Microbot Medical's return on equity of -149.24% beat Organovo's return on equity.
Microbot Medical has lower revenue, but higher earnings than Organovo. Microbot Medical is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks.
Summary
Microbot Medical beats Organovo on 12 of the 15 factors compared between the two stocks.
Get Organovo News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organovo Competitors List
Related Companies and Tools
